VXRT Vaxart

Vaxart to Present at the Citizens Life Sciences Conference

Vaxart to Present at the Citizens Life Sciences Conference

SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced that members of the management team will present at the Citizens Life Sciences conference taking place May 7-8, 2025.

Presentation Details:

Date and Time: Wednesday, May 7 at 1:00 PM ET

Webcast:

A live webcast will be available on the Company’s website at , and a replay of the presentation will be available for 30 days following the conclusion of the event.

Institutional investors interested in meeting with management during the conference may reach out to their Citizens representative.

About Vaxart

Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Contact

Vaxart Media and Investor Relations:

Matt Steinberg

FINN Partners



(646) 871-8481

This press release was published by a CLEAR® Verified individual.



EN
30/04/2025

Underlying

VXRTVaxart

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vaxart

 PRESS RELEASE
Free
VXRT VAXART

Vaxart to Host Virtual Stockholder Fireside Chat on Wednesday, August ...

Vaxart to Host Virtual Stockholder Fireside Chat on Wednesday, August 20 to Discuss Reverse Stock Split Proposal - ISS and Glass Lewis, leading independent proxy advisory firms, support reverse stock split proposal - - Webcast to begin at 4:30 p.m. ET / 1:30 p.m. PT - SOUTH SAN FRANCISCO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that members of the senior management team will participate in a virtual stoc...

August 14, 2025 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart Provides Business Update and Reports Second Quarter 2025 Financ...

Vaxart Provides Business Update and Reports Second Quarter 2025 Financial Results Reported positive topline data from Phase 1 clinical trial evaluating Company’s second-generation oral norovirus vaccine constructs, supporting potential for improved protection against infection    Enrolled approximately 5,000 participants in COVID-19 Phase 2b trial prior to stop work order; Follow-up for all participants dosed, including 400-person sentinel cohort continues Cash, cash equivalents and investments of $26.3 million as of June 30, 2025; Current runway into 2026 Conference call tod...

August 13, 2025 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart CEO Issues Letter to Stockholders

Vaxart CEO Issues Letter to Stockholders - Management Urges Stockholders to Vote FOR Reverse Stock Split Proposal by 11:59 p.m. Eastern Time on September 4, 2025 - SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today issued the following letter to its stockholders from its President & Chief Executive Officer, Steven Lo. Dear Vaxart, Inc. Stockholders: We deeply apprecia...

August 8, 2025 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart to Host Second Quarter 2025 Business Update and Financial Resul...

Vaxart to Host Second Quarter 2025 Business Update and Financial Results Conference Call on August 13 Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) today announced it will provide a business update and report financial results for the second quarter ended June 30, 2025, after the market close on Wednesday, August 13, 2025. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast...

August 6, 2025 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart Submits Proxy Statement for Reverse Stock Split to Support Resu...

Vaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on Nasdaq - Special Meeting of Stockholders to be Held Virtually on September 5, 2025 - - Live Stockholder Fireside Chat to be Scheduled to Answer Frequently Asked Stockholder Questions - - Nasdaq Hearings Panel Meeting Scheduled on August 14, 2025 - SOUTH SAN FRANCISCO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform...

July 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch